Business

Syngene International Reports Stellar 59% Profit Surge to Rs 87 Crore in Q1 2025

BENGALURU: Syngene International Shines in Q1 2025

Syngene International, a subsidiary of Biocon, has announced a remarkable 59% year-on-year increase in profit after tax, reaching Rs 87 crore for the first quarter ended June 2025. This impressive growth was supported by a 11% rise in revenue from operations, which totaled Rs 875 crore during the period.

Syngene Q1 profit up 59% to Rs 87 crore

Operational Highlights and Future Prospects

The company's Ebitda grew by 19% year-on-year to Rs 224 crore, with margins improving to 25% from 23% a year earlier. CEO Peter Bains attributed this growth to the successful conversion of pilot programs into long-term contracts within the Research Services division. Additionally, Syngene is making significant progress at its Biologics Unit III facility in Bengaluru and is gearing up for the launch of its Bayview site in the US later this year.

Regulatory Achievements and Financial Health

Syngene underwent over 20 client and regulatory audits in Q1, including a USFDA GCP inspection of its Human Pharmacology Unit, which concluded with no observations. The company's Biologics facility also received an Establishment Inspection Report with a Voluntary Action Indicated outcome. CFO Deepak Jain highlighted that operating Ebitda margins remained stable at around 24%, thanks to revenue growth and cost optimization efforts.

With these achievements, Syngene remains confident in meeting its full-year guidance, showcasing its resilience and strategic planning in the competitive biotech industry.